The goal of this study was to analyze case study data that suggests the value of adding CA11-19 to monitoring patients at risk of recurrence of colorectal cancer.
- EDP Biotech goes to Path C that also opens-up some new opportunities
- EDP Biotech Received U.S. Patent for CA11-19™ Biomarker, Methods and Compositions for Screening and Detecting Colorectal Cancer
- EDP Biotech Re-Certified for ISO 13485 Compliance
- Online video and print article present ColoMarker study results by BF Overholt MD
- CA11-19 Monitoring data presented at Gastrointestinal Cancer Symposia (Poster)